title: [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
abstract: Immunoglobulin (Ig) light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of Ig light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/ autonomic neuropathy. The diagnosis can be challenging, requiring a biopsy and often specialized testing to confirm the subtype of systemic disease. The goal of treatment is eradication of the monoclonal plasma cell population and suppression of the pathologic light chains which can result in organ improvement and extend patient survival. Standard treatment approaches include high dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation (SCT) or oral melphalan with dexamethasone (MelDex). The use of novel agents (thalidomide, lenalidomide and bortezomib) alone and in combination with steroids and alkylating agents has shown efficacy and continues to be explored.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Charliński
authors.forename: Artur
authors.initials: A
authors.lastname: Jurczyszyn
authors.forename: Wiesław
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D000686:Amyloidosis / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D001706:Biopsy; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007147:Immunoglobulin Light Chains; D008558:Melphalan / Q000627:therapeutic use; D033581:Stem Cell Transplantation
chemical_list: D007147:Immunoglobulin Light Chains; D003907:Dexamethasone; D008558:Melphalan